Status:
UNKNOWN
DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Conditions:
Antibody-mediated Rejection
Eligibility:
All Genders
18-65 years
Brief Summary
Kidney transplantation is the best therapy method for patients with uremia. The main factors affecting the long-term survival of the graft were chronic antibody-mediated rejection and the death of the...
Eligibility Criteria
Inclusion
- years 18-65
- single organ transplantation
- first time to accept kidney transplantation
- Triple immunosuppression protocol based on MMF, tacrolimus and glucocorticoid
- PRA negative before transplantation
- not pregnant for female
Exclusion
- Not accept MMF
- multi-organ transplantation
- pregnancy or lactation period female
- mental illness
- past tumor, peptic ulcer, severe cardiopulmonary disease, active liver disease history
- Cannot regular follow up
Key Trial Info
Start Date :
January 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04368962
Start Date
January 22 2021
End Date
December 1 2023
Last Update
May 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China, 710061